

Prion devoid of prpc  
do not show  
neurodegeneration



**ASSIGN  
BUSTER**

Prion diseases can occur spontaneously, by infection, or by hereditary mutations, but the common connection between all prion diseases is the misfolded state of prion (Cohen and Prusiner, 1998; Collinge, 2001; Aguzzi et al., 2008a). A large number of prion disease cases appear spontaneously (? 85 %), or are transmitted from individuals infected with prion diseases (? 5%). Nevertheless, a significant number (? 10%) of hereditary (familial) forms of prion diseases, due to specific mutations in the Prnp gene, have been reported in humans and other mammals (Mead, 2006). Mutations in the Prnp gene that are associated with prion diseases can be broadly divided into two categories: mutations that cause changes in the protein and induce prion diseases, and mutations that prevent prion disease propagation (Jones et al., 2006; Aguzzi et al., 2008a; Van der Kamp and Daggett, 2009; Coleman et al., 2014; Asante et al., 2015; Singh and Udgaonkar, 2015; Sabareesan and Udgaonkar, 2016; Sabareesan and Udgaonkar, 2017). Despite the fact that pathogenic mutations show different effects on PrP, it is very unlikely that TSEs are induced by the loss of functional PrPC due to its misfolding, because mice devoid of PrPC do not show neurodegeneration (Büeler et al., 1993). Hence, it is possible that TSEs are caused by a gain of toxic function due to the formation of PrPSc. In some, but not all, prion diseases, the formation and accumulation of the pathological form of the prion protein, PrPSc is seen (Collinge, 2001; Aguzzi and Polymenidou, 2004; Aguzzi et al., 2008a). The progressive accumulation of PrPSc in certain prion diseases is known to correlate with the extent of severity of the disease (Prusiner et al., 1983; Caughey et al.

, 2009; Laurén et al., 2009). It appears that there is a strong correlation between prion protein misfolding and TSEs. However, increasing evidence suggests that misfolding and aggregation of PrP is an important, but not a sufficient factor in prion disease aetiology.

Although PrP<sup>Sc</sup> is well established as the infectious form, it might not be the direct cause of neurodegeneration, at least in some prion diseases. Several disease-linked mutations in animals do not result in any accumulation of such amyloid plaques (Nitrini et al., 1997; Hegde et al., 1998; Coleman et al., 2014). For example, it has been reported that the A116V mutation facilitates the formation of a transmembrane form of PrP, which leads to neurodegeneration without any detectable accumulation of PrP<sup>Sc</sup> (Hegde et al., 1998).

Despite the clear understanding about the presence of these two species, PrP<sup>C</sup> and misfolded prion protein, the mechanism of conformational conversion, as well as the final structure of the misfolded prion protein remain unclear. Although the structure of PrP<sup>C</sup> is well known, the structure of PrP<sup>Sc</sup> remains poorly defined. A detailed structural understanding of the misfolded, aggregated, protease-resistant PrP<sup>Sc</sup> is therefore essential.

In vitro studies of prion protein misfolding and aggregation invariably utilize recombinant PrP (PrP).